Unipolar Depression | Current Treatment | Detailed, Expanded Analysis (US)

Publish date: June 2016

Login to access report

In the United States, more than 32 million people suffer from unipolar depression, an indication that consists of major depressive disorder, minor depression, and dysthymia. Unipolar depression is associated with a high rate of drug treatment, which encompasses an extensive range of antidepressant treatments. However, poor patient response rates to treatment result in relatively individualized treatment patterns by both psychiatrists and primary care physicians (PCPs). This content examines psychiatrists’ and PCPs’ intricate treatment paradigms, as well as the motivations behind their prescribing decisions.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Unipolar Depression Is Diverse in Subtype and Age
        • Average Number of Unipolar Depression Patients Managed on a Monthly Basis by Subtype and Specialty (Survey Data)
        • Percentage of MDD Patients Referred by PCPs to a Psychiatrist (Survey Data)
        • Physicians' Definition of TRD by Specialty (Survey Data)
        • Percentage of Treatment-Resistant MDD Patients by Specialty (Survey Data)
        • Percentage of Unipolar Depression Patients Who Are Elderly, by Specialty (Survey Data)
        • Percentage of Elderly Patients with Unipolar Depression by Subtype and Specialty (Survey Data)
        • Percentage of Elderly MDD Patients with TRD Overall and by Specialty (Survey Data)
        • Percentage of MDD Patients by Comorbidity and Other Attributes Overall and by Specialty (Survey Data)
        • Distribution of Unipolar Depression Patients' Insurance Coverage by Specialty (Survey Data)
      • Treatment Practices
        • Polypharmacy Greatly Contributes to the MDD Treatment Paradigm
        • Time to Treatment Start
        • Treatment Rates
        • Patient Share by Product
        • Treatment Duration by Product
        • Use of Nonpharmacological Approaches
        • Line of Therapy Analysis
        • Combination/Regimen/Comedication Analysis
      • Persistency and Compliance
        • Therapeutic Compliance Is Not a Significant Treatment Obstacle
      • Sequencing of Treatment
        • Branded Therapies Are Relegated to Later Lines of Treatment
        • Patient Flow of Patients Recently Treated with Rexulti by Drug (RWD: Claims)
        • Aripiprazole Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Aripiprazole by Drug (RWD: Claims)
      • Recent/Anticipated Changes in Brand Use/Treatment Approach
        • Use of Antidepressant Treatments Will Remain Relatively Constant
        • Percentage of MDD Patients Treated with Branded Abilify by Specialty (Survey Data)
        • Percentage of MDD Patients Treated with Branded Cymbalta by Specialty (Survey Data)
    • Physician Insight on Medical Practice
      • Key Findings
      • Drivers of Treatment Selection
        • Across Drug Classes, the Same Attributes Influence Prescribing Decisions
        • Factors Influencing Treatment and Disease Management
        • Major Drivers of Brand Use/Treatment
        • Major Obstacles to Brand Use/Treatment
        • Rationale for Treatment Switching by Therapy/Approach
        • Rationale for Therapy Discontinuation
        • Rationale for Treatment Deferral by Therapy/Approach
      • Face-to-Face Product Detailing Effectiveness
        • Representatives' Detailing Methods Vary by Therapies' Market Availability
        • Sales Representative Frequency and Reach
        • Sales Representative Satisfaction
        • Message Recall
    • Methodology
      • Primary Market Research Methodology
      • Respondents' Primary Practice Location by State (Survey Data)
      • Respondents' Length of Clinical Practice by Specialty (Survey Data)
      • Currently Prescribed Drug Classes for Unipolar Depression (Survey Data)
      • RWD Methodology
      • Limitations of Comparative Analyses Between Data Sources
    • Appendix
      • Primary Market Research
        • Physicians' Primary Practice Location by Specialty (Survey Data)
        • Percentage of PCPs Who Continue to Treat MDD Patients Referred to a Psychiatrist (Survey Data)
      • Claims Data
        • Claims Data Note
        • Treatment Duration by Product Among Recently Treated Patients Diagnosed with Depression (RWD: Claims)
        • Patient Share by Product Among Recently Treated Patients Diagnosed with Depression (RWD: Claims)
        • Source of Business by Product Among Recently Treated Patients Diagnosed with Depression (RWD: Claims)
        • Compliance by Brand Among Patients Newly Diagnosed with Depression (RWD: Claims)
        • Persistency by Brand Among Patients Newly Diagnosed with Depression (RWD: Claims)
        • Benzodiazepines Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Benzodiazepines by Drug (RWD: Claims)
        • Brintellix Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Brintellix by Drug (RWD: Claims)
        • Bupropion Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Bupropion by Drug (RWD: Claims)
        • Citalopram Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Citalopram by Drug (RWD: Claims)
        • Duloxetine Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Duloxetine by Drug (RWD: Claims)
        • Escitalopram Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Escitalopram by Drug (RWD: Claims)
        • Emsam Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Emsam by Drug (RWD: Claims)
        • Fetzima Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Fetzima by Drug (RWD: Claims)
        • Mirtazapine Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Mirtazapine by Drug (RWD: Claims)
        • Quetiapine Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Quetiapine by Drug (RWD: Claims)
        • Seroquel XR Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Seroquel XR by Drug (RWD: Claims)
        • Venlafaxine Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Venlafaxine by Drug (RWD: Claims)
        • Viibryd Newly Diagnosed Patient Flow by Drug (RWD: Claims)
        • Patient Flow of Patients Recently Treated with Viibryd by Drug (RWD: Claims)
      • Electronic Health Records Data
        • Gender Distribution Among Patients Diagnosed with Depression (RWD: EHR)
        • Body Mass Index Distribution Among Patients Diagnosed with Depression (RWD: EHR)
        • Race Distribution Among Patients Diagnosed with Depression (RWD: EHR)
        • Treatment Rate for Patients Diagnosed with Depression (RWD: EHR)

Author(s): Lisa Cloonan, BA

Lisa joined Decision Resources Group in 2015 as a business insights analyst for the Central Nervous System and Ophthalmology division. In this role, she analyzes the commercial opportunities for pharmacological therapies across the psychiatry space. Prior to joining Decision Resources Group, Lisa spent 6 years in clinical stroke research at Massachusetts General Hospital. While in the clinical research field, Lisa developed an expertise in neuroimaging analysis, as well as authored and co-authored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. Lisa holds bachelor of arts from Connecticut College, where her course work focused on behavioral neuroscience.